- Home
- MNMD vs BRSP Comparison
MNMD vs BRSP Comparison
Compare MNMD & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- BRSP
- Stock Information
- Founded
- MNMD 2019
- BRSP 2017
- Country
- MNMD United States
- BRSP United States
- Employees
- MNMD N/A
- BRSP N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- BRSP Real Estate Investment Trusts
- Sector
- MNMD Health Care
- BRSP Real Estate
- Exchange
- MNMD Nasdaq
- BRSP Nasdaq
- Market Cap
- MNMD 811.9M
- BRSP 764.4M
- IPO Year
- MNMD N/A
- BRSP 2018
- Fundamental
- Price
- MNMD $12.51
- BRSP $5.10
- Analyst Decision
- MNMD Strong Buy
- BRSP Buy
- Analyst Count
- MNMD 6
- BRSP 3
- Target Price
- MNMD $26.50
- BRSP $6.00
- AVG Volume (30 Days)
- MNMD 1.8M
- BRSP 687.3K
- Earning Date
- MNMD 11-06-2025
- BRSP 10-28-2025
- Dividend Yield
- MNMD N/A
- BRSP 12.40%
- EPS Growth
- MNMD N/A
- BRSP N/A
- EPS
- MNMD N/A
- BRSP N/A
- Revenue
- MNMD N/A
- BRSP $335,107,000.00
- Revenue This Year
- MNMD N/A
- BRSP N/A
- Revenue Next Year
- MNMD N/A
- BRSP $6.74
- P/E Ratio
- MNMD N/A
- BRSP N/A
- Revenue Growth
- MNMD N/A
- BRSP N/A
- 52 Week Low
- MNMD $4.70
- BRSP $4.16
- 52 Week High
- MNMD $12.94
- BRSP $6.45
- Technical
- Relative Strength Index (RSI)
- MNMD 66.16
- BRSP 26.35
- Support Level
- MNMD $11.81
- BRSP $5.07
- Resistance Level
- MNMD $12.94
- BRSP $5.51
- Average True Range (ATR)
- MNMD 0.86
- BRSP 0.11
- MACD
- MNMD 0.17
- BRSP -0.07
- Stochastic Oscillator
- MNMD 88.48
- BRSP 4.78
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.